SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The Federal Reserves rate hike and signal that further tightening may follow have driven attention to IWM, with traders highlighting higher yields and small caps rate sensitivity as pressure on the Russell 2000. The community is largely bearish amid technical weakness and put activity, though some traders argue the move is oversold and anticipate a relief bounce.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Ninth Circuit ruling that states can regulate or ban sports event contracts is driving attention, with traders viewing the setback for Kalshi and other prediction markets as a potential competitive win for DraftKings ahead of football season. Debate remains over whether the decision ultimately helps DraftKings, which is also expanding its own prediction-market business, as further appeals and regulatory uncertainty persist.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Anticipation of HLP003s pivotal Phase 3 APPROACH readout is driving attention after enrollment was completed ahead of schedule, keeping topline data on track for Q4 2026. Traders are largely bullish on the program, reinforced by the new CEO and reported insider buying, while others warn that dilution, profit-taking, and binary clinical risk could increase volatility.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA approval of FAYUVI, the first approved treatment for Sanfilippo syndrome Type A, along with a Priority Review Voucher, is driving attention around Ultragenyx. Traders are broadly bullish on the new commercial asset and potential short covering, while skeptics cite the limited patient population, treatment risks, commercialization challenges, and ongoing cash burn to explain the relatively muted reaction.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is drawing attention after a sharp selloff tied to the failed or contested Salad and Go acquisition, alongside concerns that its growth-stock valuation is too high amid weaker consumer spending, elevated rates, and competition. Traders are split between viewing the decline as an oversold buying opportunity supported by continued store expansion and seeing further downside from slowing growth, potential dilution, and heavy short interest.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins expanded share-repurchase program is the dominant catalyst, with traders viewing the buybacks as evidence of undervaluation and a potential reduction in the float. Others argue the program is masking selling by Centurium and keeping the OTC stock range-bound, while speculation about a future relisting adds to the debate.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs rally is being linked by traders to Zcashs strength, with speculation that capital is rotating between the two tokens and that NEAR could catch up after lagging. Sentiment is broadly bullish, though some traders caution that the move may be a short-term pump facing technical resistance and potential pullback.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Barclays bullish reassessment, supported by a physician survey on Lifileucels durability, has intensified attention ahead of Iovances IOV-LUN-202 lung-cancer update and anticipated guidance revision. Traders are largely bullish on the commercial trajectory and upcoming catalysts, while others attribute the rally to profit-taking, options activity, or short covering.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

Speculation that Volkswagen may reduce or divest its QuantumScape stake is driving attention, with traders debating whether this reflects balance-sheet needs or weakening confidence in the partnership. The discussion is compounded by frustration over limited Eagle Line manufacturing data and the lack of a concrete commercialization update, while some remain bullish on QSs solid-state technology and licensing relationship with PowerCo.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs Investor Day announcements are driving attention, including an upgraded full-year outlook following the SkyWater acquisition, the Superion 256 platform launch, and a quantum-safe security agreement with Congruity360. Traders are split between viewing the updates as evidence of commercialization and manufacturing progress and calling the move a sell-the-news rally, citing valuation, cash burn, and uncertainty over execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

No more this year

One more

Two more

The Federal Reserve raised interest rates by a quarter point to a range of 3.75%-4.00% on Wednesday, its first hike since July 2023, but Fed Chair Kevin Warsh signaled the tightening cycle isn't over. How many more rate hikes do you expect by the end of 2026? Vote and explain your reasoning in the comments.

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it&#39;s not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Stocktwits

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it's not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	N/A
50-Day Moving Average	N/A
Beta	N/A
Avg. Volume	N/A
PE Ratio	N/A

52-Week High	N/A
52-Week Low	N/A
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

SWN.DL1024 Fundamentals